Prostate cancer prevention trials in the USA.

[1]  P. Boyle,et al.  Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. , 1999, Urology.

[2]  P. Feigl,et al.  Prostate Cancer Prevention Trial (PCPT) Update , 1999, European Urology.

[3]  P. Ekman.  Finasteride in the treatment of benign prostatic hypertrophy: an update. New indications for finasteride therapy. , 1999, Scandinavian journal of urology and nephrology. Supplementum.

[4]  E. Giovannucci.  Selenium and risk of prostate cancer , 1998, The Lancet.

[5]  E. Giovannucci,et al.  Tomatoes, Lycopene, and Prostate Cancer , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[6]  E. di Salle,et al.  Effect of early treatment of prostate cancer with the 5α‐reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats , 1998, The Prostate.

[7]  B. Turnbull,et al.  Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. , 1998, British journal of urology.

[8]  D. Hunter,et al.  Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  L. Clark,et al.  Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. , 1998, Cancer letters.

[10]  M. Stampfer,et al.  What causes prostate cancer? A brief summary of the epidemiology. , 1998, Seminars in cancer biology.

[11]  J. Crowley,et al.  Chemoprevention of prostate cancer: The prostate cancer prevention trial , 1997, The Prostate.

[12]  J. Oesterling,et al.  Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. , 1997, Urology.

[13]  Y. Homma,et al.  Inhibition of Rat Prostate Carcinogenesis by a 5α-Reductase Inhibitor, FK143 , 1997 .

[14]  E. di Salle,et al.  Effect of turosteride, a 5α‐reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma , 1997 .

[15]  J. Palmgren,et al.  Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. , 1996, Journal of the National Cancer Institute.

[16]  M. Elhilali,et al.  Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[17]  J. Trachtenberg.  Healthcare resources should be targeted to chemoprevention: the argument against. , 1996, European urology.

[18]  J. Oesterling,et al.  The effect of finasteride on prostate specific antigen: review of available data. , 1996, The Journal of urology.

[19]  H. Akaza,et al.  Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. , 1995, Journal of the National Cancer Institute.

[20]  J. Crowley,et al.  Design of the Prostate Cancer Prevention Trial (PCPT). , 1995, Controlled clinical trials.

[21]  J. Geller.  Clinical review: 67: Approach to chemoprevention of prostate cancer. , 1995, The Journal of clinical endocrinology and metabolism.

[22]  C. Vicentini,et al.  Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. , 1995, Urology.

[23]  G. Gormley,et al.  Finasteride: a clinical review. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[24]  B. Kramer,et al.  5-Alpha-reductase inhibition and prostate cancer prevention. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  E. Stoner,et al.  Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. , 1994, Urology.

[26]  pierre-Marie Martin,et al.  Inhibition of the activity of ‘basic’ 5α-reductase (type 1) detected in DU 145 cells and expressed in insect cells , 1994, Journal of Steroid Biochemistry and Molecular Biology.

[27]  S. Lippman,et al.  Second international cancer chemoprevention conference. , 1994, Cancer research.

[28]  J. Fraumeni,et al.  Design, Methods, Participant Characteristics, and Compliance , 1993 .

[29]  P. Ekman.  [Finasteride in the treatment of benign prostatic hypertrophy]. , 1993, Journal d'urologie.